{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:57:02Z","timestamp":1782903422756,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-02023-w","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:36:09Z","timestamp":1762425369000},"page":"557-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives of patients with rheumatoid arthritis towards the use of parenteral methotrexate: a qualitative study"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3660-6496","authenticated-orcid":false,"given":"Jiun Ming","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Desforges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-4341","authenticated-orcid":false,"given":"Wern Chern","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-9884","authenticated-orcid":false,"given":"Susanna M.","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-9242","authenticated-orcid":false,"given":"Michael D.","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-999X","authenticated-orcid":false,"given":"Emily","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"10055","key":"2023_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/s0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338. https:\/\/doi.org\/10.1016\/s0140-6736(16)30173-8.","journal-title":"Lancet"},{"issue":"6","key":"2023_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"2023_CR3","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(17)31491-5.","journal-title":"Lancet"},{"issue":"1","key":"2023_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000171","volume":"2","author":"HF Hope","year":"2016","unstructured":"Hope HF, Bluett J, Barton A, et al. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open. 2016;2(1):e000171. https:\/\/doi.org\/10.1136\/rmdopen-2015-000171.","journal-title":"RMD Open"},{"issue":"1","key":"2023_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/kez274","volume":"59","author":"HF Hope","year":"2019","unstructured":"Hope HF, Hyrich KL, Anderson J, et al. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatology. 2019;59(1):213\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/kez274.","journal-title":"Rheumatology"},{"issue":"4","key":"2023_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/mr\/roac156","volume":"33","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y. Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2022;33(4):633\u20139. https:\/\/doi.org\/10.1093\/mr\/roac156.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"2023_CR7","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s11096-025-01904-4","volume":"47","author":"MAM Oude Lansink","year":"2025","unstructured":"Oude Lansink MAM, Pongers SAS, Bekker CL, et al. Drug-related problems experienced by rheumatoid arthritis patients during the first three months of methotrexate use: a longitudinal observational study. Int J Clin Pharm. 2025;47(3):884\u201390. https:\/\/doi.org\/10.1007\/s11096-025-01904-4.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"2023_CR8","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"2023_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","volume":"33","author":"G Bianchi","year":"2016","unstructured":"Bianchi G, Caporali R, Todoerti M, et al. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33(3):369\u201378. https:\/\/doi.org\/10.1007\/s12325-016-0295-8.","journal-title":"Adv Ther"},{"issue":"5","key":"2023_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00296-016-3447-x","volume":"36","author":"S Yadlapati","year":"2016","unstructured":"Yadlapati S, Efthimiou P. Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics? Rheumatol Int. 2016;36(5):627\u201333. https:\/\/doi.org\/10.1007\/s00296-016-3447-x.","journal-title":"Rheumatol Int"},{"issue":"11","key":"2023_CR11","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/acr.25141","volume":"75","author":"JM Tan","year":"2023","unstructured":"Tan JM, Reeve E, Fraser L, et al. Barriers and enablers in the use of parenteral methotrexate in rheumatoid arthritis patients: a scoping review. Arthritis Care Res (Hoboken). 2023;75(11):2306\u201315. https:\/\/doi.org\/10.1002\/acr.25141.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2023_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/acr.23329","volume":"70","author":"A Kelly","year":"2018","unstructured":"Kelly A, Tymms K, Tunnicliffe DJ, et al. Patients\u2019 attitudes and experiences of disease-modifying antirheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis. Arthritis Care Res. 2018;70(4):525\u201332. https:\/\/doi.org\/10.1002\/acr.23329.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2023_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"2023_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2147\/ppa.S170721","volume":"12","author":"EG Mathijssen","year":"2018","unstructured":"Mathijssen EG, van Heuckelum M, van Dijk L, et al. A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels. Patient Prefer Adherence. 2018;12:1537\u201355. https:\/\/doi.org\/10.2147\/ppa.S170721.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2023_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88. https:\/\/doi.org\/10.1186\/s12913-017-2031-8.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"2023_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/acr.23152","volume":"69","author":"MK Rohr","year":"2017","unstructured":"Rohr MK, Mikuls TR, Cohen SB, et al. Underuse of methotrexate in the treatment of rheumatoid arthritis: a national analysis of prescribing practices in the US. Arthritis Care Res (Hoboken). 2017;69(6):794\u2013800. https:\/\/doi.org\/10.1002\/acr.23152.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"S2","key":"2023_CR17","doi-asserted-by":"publisher","first-page":"P38","DOI":"10.1111\/imj.15302","volume":"51","author":"J Ye","year":"2021","unstructured":"Ye J, Marson A, Sinnathurai P, et al. ARA Abstracts: patterns of use of b\/tsDMARDS and other medications for patients with rheumatoid arthritis: a retrospective study using PBS data. Intern Med J. 2021;51(S2):P38. https:\/\/doi.org\/10.1111\/imj.15302.","journal-title":"Intern Med J"},{"issue":"S1","key":"2023_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/imj.16057","volume":"53","author":"JM Tan","year":"2023","unstructured":"Tan JM, Reeve E, Chia WC, et al. ARA Abstracts: attitudes of healthcare professional towards the use of parenteral methotrexate in rheumatoid arthritis patients: A qualitative study. Intern Med J. 2023;53(S1):46. https:\/\/doi.org\/10.1111\/imj.16057.","journal-title":"Intern Med J"},{"key":"2023_CR19","unstructured":"The Australian Pharmaceutical Benefits Scheme. Public Summary Document \u2013 March 2017 PBAC Meeting. 2017. https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2017-03\/methotrexate-psd-march-2017. Accessed 01.08.2023."},{"key":"2023_CR20","unstructured":"The Australian Pharmaceutical Benefits Scheme. Methotrexate - Pharmaceutical Benefits Scheme (PBS) 2023 [Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/11268C-11275K-11283W-11288D-11295L. Accessed 01.08.2023."},{"issue":"9","key":"2023_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/acm.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351. https:\/\/doi.org\/10.1097\/acm.0000000000000388.","journal-title":"Acad Med"},{"issue":"5","key":"2023_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","volume":"42","author":"LA Palinkas","year":"2015","unstructured":"Palinkas LA, Horwitz SM, Green CA, et al. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533\u201344. https:\/\/doi.org\/10.1007\/s10488-013-0528-y.","journal-title":"Adm Policy Ment Health"},{"issue":"13","key":"2023_CR23","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360. https:\/\/doi.org\/10.1177\/1049732315617444.","journal-title":"Qual Health Res"},{"issue":"4","key":"2023_CR24","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907. https:\/\/doi.org\/10.1007\/s11135-017-0574-8.","journal-title":"Qual Quant"},{"issue":"4","key":"2023_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0976-0105.141942","volume":"5","author":"S Jamshed","year":"2014","unstructured":"Jamshed S. Qualitative research method-interviewing and observation. J Basic Clin Pharm. 2014;5(4):87\u20138. https:\/\/doi.org\/10.4103\/0976-0105.141942.","journal-title":"J Basic Clin Pharm"},{"issue":"9","key":"2023_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"issue":"7294","key":"2023_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/bmj.322.7294.1115","volume":"322","author":"RS Barbour","year":"2001","unstructured":"Barbour RS. Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? BMJ. 2001;322(7294):1115\u20137. https:\/\/doi.org\/10.1136\/bmj.322.7294.1115.","journal-title":"BMJ"},{"issue":"7","key":"2023_CR28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00393-012-1038-0","volume":"71","author":"K Kruger","year":"2012","unstructured":"Kruger K, Wollenhaupt J, Albrecht K. S1-Leitlinie der DGRh zur sequenziellen medikamentosen Therapie der rheumatoiden Arthritis 2012. Adaptierte EULAR-Empfehlungen und aktualisierter Therapiealgorithmus [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol. 2012;71(7):592\u2013603.","journal-title":"Z Rheumatol"},{"issue":"3","key":"2023_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.reuma.2016.12.001","volume":"14","author":"J Tornero Molina","year":"2018","unstructured":"Tornero Molina J, Calvo Alen J, Ballina J, et al. Recommendations for the use of parenteral methotrexate in rheumatic diseases. Reumatol Clin. 2018;14(3):142\u20139. https:\/\/doi.org\/10.1016\/j.reuma.2016.12.001.","journal-title":"Reumatol Clin"},{"key":"2023_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"2023_CR31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian rheumatology association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559\u201382.","journal-title":"J Rheumatol"},{"issue":"6","key":"2023_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/rheumatology\/kel216a","volume":"47","author":"K Chakravarty","year":"2008","unstructured":"Chakravarty K, McDonald H, Pullar T, et al. BSR\/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. 2008;47(6):924\u20135.","journal-title":"Rheumatology"},{"issue":"5","key":"2023_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/193229680700100517","volume":"1","author":"HS Gill","year":"2007","unstructured":"Gill HS, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol. 2007;1(5):725\u20139. https:\/\/doi.org\/10.1177\/193229680700100517.","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"2023_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006918","volume":"5","author":"C Hayden","year":"2015","unstructured":"Hayden C, Neame R, Tarrant C. Patients\u2019 adherence-related beliefs about methotrexate: a qualitative study of the role of written patient information. BMJ Open. 2015;5(5):e006918-e. https:\/\/doi.org\/10.1136\/bmjopen-2014-006918.","journal-title":"BMJ Open"},{"key":"2023_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9010007","author":"LA Hillman","year":"2020","unstructured":"Hillman LA, Peden-McAlpine C, Ramalho-de-Oliveira D, et al. The medication experience: a concept analysis. Pharmacy (Basel). 2020. https:\/\/doi.org\/10.3390\/pharmacy9010007.","journal-title":"Pharmacy (Basel)"},{"issue":"1","key":"2023_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1370\/afm.238","volume":"3","author":"JE Aikens","year":"2005","unstructured":"Aikens JE, Nease DE Jr, Nau DP, et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3(1):23\u201330. https:\/\/doi.org\/10.1370\/afm.238.","journal-title":"Ann Fam Med"},{"key":"2023_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01944-w","author":"O Omonaiye","year":"2025","unstructured":"Omonaiye O, Mekonnen A, Gilfillan C, et al. Barriers to, and enablers of, medication taking among Chinese adults living with type 2 diabetes mellitus in Australia: a qualitative study. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01944-w.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"2023_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.5694\/mja16.00965","volume":"205","author":"MH Arnold","year":"2016","unstructured":"Arnold MH, Bleasel J, Haq I. Nocebo effects in practice: methotrexate myths and misconceptions. Med J Aust. 2016;205(10):440\u20132. https:\/\/doi.org\/10.5694\/mja16.00965.","journal-title":"Med J Aust"},{"issue":"8","key":"2023_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jval.2014.08.2670","volume":"17","author":"A Higgins","year":"2014","unstructured":"Higgins A, Barnett J, Meads C, et al. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health. 2014;17(8):877\u201387. https:\/\/doi.org\/10.1016\/j.jval.2014.08.2670.","journal-title":"Value Health"},{"issue":"3","key":"2023_CR40","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/humrep\/der449","volume":"27","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Jablonowska B, Norlander E, et al. Patient preferences for characteristics differentiating ovarian stimulation treatments. Hum Reprod. 2012;27(3):760\u20139. https:\/\/doi.org\/10.1093\/humrep\/der449.","journal-title":"Hum Reprod"},{"issue":"10","key":"2023_CR41","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jsps.2021.09.004","volume":"29","author":"A Roy","year":"2021","unstructured":"Roy A, Geetha RV, Magesh A, et al. Autoinjector - a smart device for emergency cum personal therapy. Saudi Pharm J. 2021;29(10):1205\u201315. https:\/\/doi.org\/10.1016\/j.jsps.2021.09.004.","journal-title":"Saudi Pharm J"},{"key":"2023_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/oarrr.S306378","volume":"13","author":"J Nilsson","year":"2021","unstructured":"Nilsson J, Andersson MLE, Hafstr\u00f6m I, et al. Influence of age and sex on disease course and treatment in rheumatoid arthritis. Open Access Rheumatol. 2021;13:123\u201338. https:\/\/doi.org\/10.2147\/oarrr.S306378.","journal-title":"Open Access Rheumatol"},{"issue":"13","key":"2023_CR43","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1177\/1049732318788379","volume":"28","author":"L Carminati","year":"2018","unstructured":"Carminati L. Generalizability in qualitative research: a tale of two traditions. Qual Health Res. 2018;28(13):2094\u2013101. https:\/\/doi.org\/10.1177\/1049732318788379.","journal-title":"Qual Health Res"},{"issue":"6","key":"2023_CR44","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/03009742.2014.910312","volume":"43","author":"DG Scott","year":"2014","unstructured":"Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014;43(6):470\u20136. https:\/\/doi.org\/10.3109\/03009742.2014.910312.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"2023_CR45","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","volume":"75","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1003\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206504.","journal-title":"Ann Rheum Dis"},{"key":"2023_CR46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fphar.2020.00420","volume":"11","author":"RJ Tyson","year":"2020","unstructured":"Tyson RJ, Park CC, Powell JR, et al. Precision dosing priority criteria: drug, disease, and patient population variables. Front Pharmacol. 2020;11:420. https:\/\/doi.org\/10.3389\/fphar.2020.00420.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2023_CR47","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard.53.7.475","volume":"53","author":"C Lebbe","year":"1994","unstructured":"Lebbe C, Beyeler C, Gerber NJ, et al. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis. 1994;53(7):475. https:\/\/doi.org\/10.1136\/ard.53.7.475.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2023_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cpt.2064","volume":"109","author":"RW Peck","year":"2021","unstructured":"Peck RW. Precision dosing: an industry perspective. Clin Pharmacol Ther. 2021;109(1):47\u201350. https:\/\/doi.org\/10.1002\/cpt.2064.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2023_CR49","first-page":"85","volume":"15","author":"SWY Yip","year":"2020","unstructured":"Yip SWY, Chong GCH. The role and responsibility of clinical pharmacists in rheumatology clinic: an exploratory study in Hong Kong. Asia Pac J Health Manag. 2020;15(2):85\u201390.","journal-title":"Asia Pac J Health Manag"},{"issue":"1","key":"2023_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3540-z","volume":"20","author":"AA Naqvi","year":"2019","unstructured":"Naqvi AA, Hassali MA, Naqvi SBS, et al. Impact of pharmacist educational intervention on disease knowledge, rehabilitation and medication adherence, treatment-induced direct cost, health-related quality of life and satisfaction in patients with rheumatoid arthritis: study protocol for a randomized controlled trial. Trials. 2019;20(1):488. https:\/\/doi.org\/10.1186\/s13063-019-3540-z.","journal-title":"Trials"},{"issue":"4","key":"2023_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1756-185X.2012.01738.x","volume":"15","author":"L-C Chew","year":"2012","unstructured":"Chew L-C, Lim TG, Loy KL, et al. A questionnaire survey of patient experience with the Rheumatology Monitoring Clinic in Singapore. Int J Rheum Dis. 2012;15(4):390\u20138. https:\/\/doi.org\/10.1111\/j.1756-185X.2012.01738.x.","journal-title":"Int J Rheum Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02023-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02023-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02023-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:05:11Z","timestamp":1773662711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02023-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02023-w","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study complies with the Declaration of Helsinki. The Central Adelaide Local Health Network (CALHN) Human Research Ethics Committee and University of South Australia's Human Research Ethics Committee have approved the research protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the subjects included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}